Home  »  Business   »  Selling Your Microbot Medical Inc. (NASDAQ: MBOT) ...

Selling Your Microbot Medical Inc. (NASDAQ: MBOT) Stock? Here’s What You Need To Know

Microbot Medical Inc. (NASDAQ:MBOT) shares, rose in value on Thursday, 05/25/23, with the stock price up by 10.99% to the previous day’s close as strong demand from buyers drove the stock to $2.12.

Actively observing the price movement in the last trading, the stock closed the session at $1.91, falling within a range of $1.91 and $2.35. Referring to stock’s 52-week performance, its high was $6.33, and the low was $1.00. On the whole, MBOT has fluctuated by 39.02% over the past month.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


With the market capitalization of Microbot Medical Inc. currently standing at about $15.86 million, investors are eagerly awaiting this quarter’s results, scheduled for Aug 14, 2023 – Aug 18, 2023.


Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MBOT’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

1 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 1 recommend it as a Buy and 0 called the MBOT stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MBOT currently trading nearly 51.45% and 20.63% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 57.30, while the 7-day volatility ratio is showing 56.58% which for the 30-day chart, stands at 25.11%. Furthermore, Microbot Medical Inc. (MBOT)’s beta value is 3.17, and its average true range (ATR) is 0.43. The company’s stock has been forecasted to trade at an average price of $8.00 over the course of the next 52 weeks, with a low of $8.00 and a high of $8.00. Based on these price targets, the low is -277.36% off current price, whereas the price has to move -277.36% to reach the yearly target high. Additionally, analysts’ median price of $8.00 is likely to be welcomed by investors because it represents a decrease of -277.36% from the current levels.


Data on historical trading for Microbot Medical Inc. (NASDAQ:MBOT) indicates that the trading volumes over the past 10 days have averaged 21.76 million and over the past 3 months, they’ve averaged 3.48 million. According to company’s latest data on outstanding shares, there are 7.72 million shares outstanding.

Nearly 2.98% of Microbot Medical Inc.’s shares belong to company insiders and institutional investors own 21.00% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 81010.0 shares as on May 14, 2023, resulting in a short ratio of 0.89. According to the data, the short interest in Microbot Medical Inc. (MBOT) stood at 1.00% of shares outstanding as of May 14, 2023; the number of short shares registered in Apr 13, 2023 reached 53900.0. The stock has fallen by -29.57% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MBOT stock heading into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *